Objective
Seeks long-term capital appreciation.
Overview
A stock fund that invests exclusively in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.
The Health-Care Revolution
The health-care sector is undergoing dramatic changes that will impact everything from the drugs we take to the way patients’ medical records are shared. Aging demographics globally and rising prosperity in emerging-market nations will drive even greater demand for lifesaving drugs, innovative procedures, and disruptive medical technology.
Pipeline to Innovation
With innovation and breakthroughs taking place across the globe, the Fund uses a broadly diversified, global approach that seeks to identify companies with the greatest opportunities in areas including biotechnology, medical technology, health services, and pharmaceuticals.
Backed by Size, Scale, and Experience
Wellington Management, the Fund’s sub-adviser, is one of the largest managers of health care stocks in the world. The portfolio managers on the Fund average 26 years of experience.
The portfolio managers are supported by the full resources of Wellington.
Average Annual Total Returns % (as of 12/31/2020)
|
|||||
1YR | 5YR | 10YR | SI | ||
---|---|---|---|---|---|
Hartford Healthcare I | 22.91 | 12.30 | 17.41 | 12.53 | |
Benchmark | 14.55 | 12.12 | 16.16 | --- | |
Morningstar Health Category | 27.63 | 11.77 | 15.97 | --- |
Average Annual Total Returns % (as of 12/31/2020)
|
|||||
1YR | 5YR | 10YR | SI | ||
---|---|---|---|---|---|
Hartford Healthcare I | 22.91 | 12.30 | 17.41 | 12.53 | |
Benchmark | 14.55 | 12.12 | 16.16 | --- | |
Morningstar Health Category | 27.63 | 11.77 | 15.97 | --- |
Class I-share performance prior to its inception date reflects Class A-share performance (excluding sales charges) and operating expenses. SI performance is calculated from 5/1/00.
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.
Growth of $10,000 (I-Share)
(as of 12/31/2020)
Fund | BENCHMARK | |
---|---|---|
2020 | 22.91 | 14.55 |
2019 | 33.69 | 20.87 |
2018 | -2.74 | 6.71 |
2017 | 21.94 | 22.47 |
2016 | -8.33 | -2.05 |
2015 | 12.97 | 7.41 |
2014 | 26.80 | 24.79 |
2013 | 49.95 | 42.19 |
2012 | 20.14 | 18.35 |
2011 | 8.03 | 11.88 |
Excludes sales charges. If sales charges and taxes had been included, the value would have been lower.
CharacteristicsAllocations, exposures and holdings are subject to change. Percentages may be rounded.
As of Date | 12/31/2020 |
Net Assets | $1.6 billion |
# of Holdings | 106 |
% in Equities | 98 |
% in Foreign Equities | 18 |
Beta (3 year) | 1.05 |
R Squared (3 year) | 0.88 |
Standard Deviation | 18.62% |
Turnover (12/31/2020) | 43% |
Active Share | 57% |
Fund | S&P Composite 1500 Health Care Index | |
---|---|---|
Price/Earnings | 31.5x | 16.5x |
Price/Book | 5.6x | 5.1x |
EPS Growth Rate | 11.8% | 9.4% |
Return on Equity | 5.5% | 23.2% |
Asset Weighted Market Cap (billions) | $93.1 | $147.8 |
Median Market Cap (billions) | $6.6 | $5.5 |
Fund | |
---|---|
Alpha (5 Year) | -0.68 |
Down Capture (5 Year) | 113.11 |
Information Ratio (5 Year) | 0.03 |
Sharpe Ratio (5 Year) | 0.69 |
Up Capture (5 Year) | 108.28 |
Fund | |
---|---|
Less than $2 billion | 8 |
$2 billion - $5 billion | 7 |
$5 billion - $10 billion | 10 |
Greater than $10 billion | 75 |
Not Classified | 0 |
Regional Exposure (%)
label | value |
---|---|
North America | 82 |
Europe | 10 |
Japan | 4 |
Emerging Markets | 4 |
Middle East/Developed | 1 |
label | value |
---|---|
North America | 82 |
Europe | 11 |
Japan | 4 |
Emerging Markets | 3 |
Middle East/Developed | 0 |
Top Ten Holdings (%)
label | percentageholding |
---|---|
UnitedHealth Group, Inc. | 8.26 |
Pfizer, Inc. | 5.35 |
Eli Lilly & Co. | 4.59 |
Thermo Fisher Scientific, Inc. | 4.20 |
Danaher Corp. | 3.43 |
Bristol-Myers Squibb Co. | 3.42 |
Abbott Laboratories | 3.28 |
Boston Scientific Corp. | 2.88 |
Edwards Lifesciences Corp. | 2.69 |
AstraZeneca plc | 2.55 |
Total Portfolio % | 40.65 |
label | percentageholding |
---|---|
UnitedHealth Group, Inc. | 7.79 |
Pfizer, Inc. | 5.87 |
Thermo Fisher Scientific, Inc. | 4.38 |
Danaher Corp. | 3.66 |
Bristol-Myers Squibb Co. | 3.65 |
Abbott Laboratories | 3.58 |
Eli Lilly and Co. | 3.56 |
Boston Scientific Corp. | 2.99 |
AstraZeneca plc | 2.70 |
Edwards Lifesciences Corp. | 2.59 |
Total Portfolio % | 40.77 |
Inception Date | 05/01/2000 |
Symbol | HGHIX |
CUSIP | 416649887 |
Fund Number | 1309 |
Subsector Exposure
label | currentpercentage |
---|---|
Medical Technology | 32 |
Biopharma Large Cap | 26 |
Health Care Services | 22 |
Biopharma Mid Cap | 12 |
Biopharma Small Cap | 7 |
label | currentpercentage |
---|---|
Medical Technology | 33 |
Biopharma Large Cap | 25 |
Health Care Services | 21 |
Biopharma Mid Cap | 11 |
Biopharma Small Cap | 10 |
.jpg/_jcr_content/renditions/cq5dam.thumbnail.540.360.margin.jpeg)
2021 Outlooks (Wellington)
12/14/2020
Five Common COVID-19 Questions
11/16/2020Financial Professionals:
Log in to order forms and literature and manage your subscriptions.
-
Add to favorite(0)
-
Email(0)
-
Add to Cart(0)
Fund LiteratureSelect All
0 items Selected
|
Fact Sheet12/31/2020 | pdfThis client flyer summarizes the Fund's investment approach, portfolio statistics, top holdings, and current performance. |
Fund Story09/30/2020 | pdfThis Fund Story outlines three distinguishing characteristics to help investors better understand the Fund.
|
Commentary12/31/2020 | pdfCurrent quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund. |
Expanded Commentary09/30/2020 | pdfCurrent quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
|
Summary ProspectuspdfA concise summary of the Fund’s investment strategy, performance, expenses, risks, and management team.
|
Healthcare Fund Pitchbook12/31/2020 | pdfThis Pitchbook reviews the Funds' investment approach, investment team, investment process, and general portfolio parameters.
|
Semi Annual ReportpdfA semi-annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.
|
Statutory ProspectuspdfAn annual update on the Fund that includes information about the Fund’s investment manager, sub-adviser, and operations.
|
Annual ReportpdfAn annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.
|
SAIpdfA supplementary document to the Fund’s prospectus that includes additional information about the Fund and its operations.
|
219387